By either modulating the interaction between the adenosine A2A receptor (A2AR) and γ-secretase or regulating the D2R-mediated β-arrestin2-dependent signalling pathway, those anti-PD drugs may contribute to AD-like pathology. This evidence concerns the gene ADORA2A and Parkinson disease.